New Stock News | Tianxing Medical passes the hearing of Hong Kong Stock Exchange, focusing on clinical solutions in sports medicine.

According to the disclosure by the Hong Kong Stock Exchange on April 7th, Beijing Tianxing Medical Company Limited (referred to as Tianxing Medical) has conducted a listing hearing on the main board of the Hong Kong Stock Exchange, with CITIC SEC and CCB International as the joint sponsors. According to the prospectus, the company is a China-based medical device company focusing on providing clinical solutions for sports medicine. Based on data from Zhi Shi Consulting, the company is the fourth largest provider of sports medicine implants and devices in China by estimated sales revenue in 2024, with a market share of approximately 6.5% in the Chinese sports medicine implants and devices market. It is also the largest domestic provider of sports medicine implants and devices. Leveraging its independently developed implants, active devices, related consumables, and surgical instruments, the company offers comprehensive solutions for the treatment of soft tissue injuries such as shoulder cuffs, ligaments, menisci in the shoulder, knee, hip, foot/ankle, elbow, hand/wrist regions, as well as sports rehabilitation and prevention. As of the latest practical date (March 31, 2026), the company's product portfolio includes 63 products, covering implants, surgical equipment, related consumables, surgical tools, and regenerative repair products. According to data from Zhi Shi Consulting, as of the same date, the company has obtained third-class medical device certificates for 27 products and second-class medical device certificates for 25 products, making it the most certified company in the Chinese sports medicine industry. Additionally, as of the latest practical date, the company has obtained over 200 medical device regulatory approvals and registrations in Europe, Southeast Asia, the Middle East, and Latin America. As of December 31, 2023, the company's products had entered more than 1,000 hospitals, which had increased to over 3,000 hospitals by December 31, 2025, with over 1,000 of them being tertiary hospitals. By December 31, 2025, the cumulative sales volume of the products exceeded 2 million units. According to data from Zhi Shi Consulting, the Chinese sports medicine equipment market is highly concentrated and currently dominated by international participants. In 2024, based on sales revenue, the top five sports medicine implants and devices providers in China accounted for approximately 59.3% of the market share, with four of them being international participants. Based on estimated sales revenue in 2024, the company ranked fourth among all brands in the Chinese sports medicine implants and tools market, with a market share of approximately 6.5%, ranking first among all Chinese brands. The company's business covers major product categories including sports medicine implants, surgical equipment, related consumables, and other sports medicine products such as articular soft tissue regeneration products. In the Chinese sports medicine implants market, based on sales revenue, the company ranked first among Chinese brands and fourth among all brands in 2024, with a market share of approximately 8.8%. In the Chinese surgical equipment and related consumables market, based on sales revenue, the company ranked first among Chinese brands and sixth among all brands in 2024, with a market share of approximately 3.2%. The Chinese sports medicine equipment industry is still in its early stages of development, with significant room for growth compared to developed countries. According to data from Zhi Shi Consulting, the Chinese sports medicine equipment market is expected to grow at a compound annual growth rate of 16.5% from 2024 to 2030. At the same time, domestic sports medicine equipment providers are expected to increase their market penetration in the Chinese sports medicine market. Additionally, the Chinese smart rehabilitation solutions market is expected to achieve a compound annual growth rate of 47.5%, reaching approximately RMB 22.9 billion by 2030. Financially, in the years 2023, 2024, and 2025, the company's revenues were approximately RMB 239 million, RMB 327 million, and RMB 403 million, respectively; during the same period, the company's net profits were approximately RMB 57.112 million, RMB 95.389 million, and RMB 137 million, respectively.